Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | 3 | 3 | — | — | — | 3 |
Urologic diseases | D014570 | — | N39.9 | 2 | 2 | — | — | — | 2 |
Urinary bladder diseases | D001745 | — | N32.9 | 2 | 2 | — | — | — | 2 |
Urinary bladder neoplasms | D001749 | — | C67 | 2 | 1 | — | — | — | 2 |
Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | — | 2 |
Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | — | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | — | 1 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 1 | — | — | — | 1 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Transitional cell carcinoma | D002295 | — | — | 1 | — | — | — | — | 1 |
Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
Drug common name | VOFATAMAB |
INN | vofatamab |
Description | Vofatamab is an antibody pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4297848 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | JMH6YR91PG (ChemIDplus, GSRS) |